How do payers view the trends in the sluggish US biosimilar market and what initiatives do they want from pharma? Originator companies are fiercely defending their brands which has slowed new product introductions and limited clinicians’ ability to build prescribing confidence with biosimilar products. While payers remain upbeat about biosimilars they are looking to pharma to deliver the evidence of safety and utility to educate and support a cautious clinical community.
What strategies are payers using to drive biosimilar usage? Will the FDA’s guidelines on interchangeability accelerate the market? Why is competition essential in the biosimilar space? To really understand how US payers see the biosimilar market playing out turn to Biosimilars: US Payer Insights (2019). This detailed report, based on in-depth interviews with experienced US payers, reveals their insights on current trends, future developments and the practical steps pharma can take now.
Payers tackle key questions such as
- How confident are payers in reimbursing biosimilars and has this level of confidence changed over the last 12 months?
- What are the best methods of educating key stakeholders about biosimilars and what needs to be the focus of such campaigns?
- Are biosimilar developers making enough effort to understand payer goals and objectives and what can they do to improve their engagement?
- What are the arguments for non-medical switching from branded to biosimilar products?
- How much of a concern to payers is the ‘rebate trap’ and have anxieties increased over the last 12 months?
- In terms of real world evidence what are payers looking for and how influential is it?
- What do payers think of pharmacy-level substitution of branded biologics for a biosimilar of the same molecule and why might this not be possible countrywide?